Allergan Plc
Latest Stories
insider_q_a_allergan_ceo_05674.jpg
This Aug. 8, 2016, photo provided by Allergan shows Brent Saunders. Saunders, CEO of Botox maker Allergan PLC, last September 2016, announced a new "social contract" under which the company would limit annual list price increases for its drugs to below 10 percent. After deducting the discounts insurers and other payers get off the higher list price, Allergan will receive net price increases of around 2 percent to 3 percent on its drugs, Saunders said. (Jeff Weiner/Allergan via AP)
